277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
April 2025 in “The Journal of Dermatology” This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.
19 citations
,
August 2019 in “Dermatologic therapy” This review discusses the use of Janus kinase inhibitors for alopecia areata and reports promising short-term efficacy but low-quality evidence, highlighting the need for further research to confirm long-term safety and effectiveness.
4 citations
,
January 2025 in “JAAD reviews.” This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.